Making antisense of splicing

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Alternative splicing multiplies the coding capacity of the genome, resulting in an expanded proteome that provides many targets for therapy. In addition to creating this diverse pharmacoproteome, the process of splicing can be targeted by conventional and molecular therapies. Splicing as a therapeutic target is highlighted in this review, with a particular emphasis on oligonucleotide-based molecular approaches. These oligonucleotides can be used to promote skipping of constitutive exons, inhibit inappropriately activated exons, or stimulate exons weakened by mutations. Preliminary, but exciting, results suggest that these reagents could have clinical utility in treating previously intractable conditions.

Original languageEnglish (US)
Pages (from-to)476-482
Number of pages7
JournalCurrent Opinion in Molecular Therapeutics
Volume7
Issue number5
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Exons
Oligonucleotides
Molecular Targeted Therapy
Alternative Splicing
Proteome
Genome
Mutation
Therapeutics

Keywords

  • Alternative splicing
  • Dystrophin
  • Oligonucleotides
  • Pre-mRNAs
  • Splice sites
  • Splicing

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Making antisense of splicing. / Garcia-Blanco, Mariano.

In: Current Opinion in Molecular Therapeutics, Vol. 7, No. 5, 10.2005, p. 476-482.

Research output: Contribution to journalArticle

@article{2239490766d847f8827ff52e73566a2f,
title = "Making antisense of splicing",
abstract = "Alternative splicing multiplies the coding capacity of the genome, resulting in an expanded proteome that provides many targets for therapy. In addition to creating this diverse pharmacoproteome, the process of splicing can be targeted by conventional and molecular therapies. Splicing as a therapeutic target is highlighted in this review, with a particular emphasis on oligonucleotide-based molecular approaches. These oligonucleotides can be used to promote skipping of constitutive exons, inhibit inappropriately activated exons, or stimulate exons weakened by mutations. Preliminary, but exciting, results suggest that these reagents could have clinical utility in treating previously intractable conditions.",
keywords = "Alternative splicing, Dystrophin, Oligonucleotides, Pre-mRNAs, Splice sites, Splicing",
author = "Mariano Garcia-Blanco",
year = "2005",
month = "10",
language = "English (US)",
volume = "7",
pages = "476--482",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "5",

}

TY - JOUR

T1 - Making antisense of splicing

AU - Garcia-Blanco, Mariano

PY - 2005/10

Y1 - 2005/10

N2 - Alternative splicing multiplies the coding capacity of the genome, resulting in an expanded proteome that provides many targets for therapy. In addition to creating this diverse pharmacoproteome, the process of splicing can be targeted by conventional and molecular therapies. Splicing as a therapeutic target is highlighted in this review, with a particular emphasis on oligonucleotide-based molecular approaches. These oligonucleotides can be used to promote skipping of constitutive exons, inhibit inappropriately activated exons, or stimulate exons weakened by mutations. Preliminary, but exciting, results suggest that these reagents could have clinical utility in treating previously intractable conditions.

AB - Alternative splicing multiplies the coding capacity of the genome, resulting in an expanded proteome that provides many targets for therapy. In addition to creating this diverse pharmacoproteome, the process of splicing can be targeted by conventional and molecular therapies. Splicing as a therapeutic target is highlighted in this review, with a particular emphasis on oligonucleotide-based molecular approaches. These oligonucleotides can be used to promote skipping of constitutive exons, inhibit inappropriately activated exons, or stimulate exons weakened by mutations. Preliminary, but exciting, results suggest that these reagents could have clinical utility in treating previously intractable conditions.

KW - Alternative splicing

KW - Dystrophin

KW - Oligonucleotides

KW - Pre-mRNAs

KW - Splice sites

KW - Splicing

UR - http://www.scopus.com/inward/record.url?scp=27144442421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144442421&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 476

EP - 482

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 5

ER -